Metabolic Stress, AMPK–SQSTM1 Feedback, and Antioxidant Defense: Mechanistic Insights from Recent Research

Study Background and Research Question

Metabolic and oxidative stresses are central features of the tumor microenvironment, especially in non-small cell lung cancer (NSCLC), where chronic inflammation leads to nutrient depletion and reactive oxygen species (ROS) accumulation. Cancer cells have evolved sophisticated mechanisms to adapt and survive these harsh conditions, with the STK11/LKB1–AMPK pathway playing a major role in maintaining ATP and NADPH levels under energy stress. However, the crosstalk between metabolic adaptation pathways—specifically between the STK11-AMPK axis and the KEAP1-NFE2L2/NRF2 antioxidant pathway—remained poorly understood. The recent study by Choi et al. addresses this gap by investigating how metabolic stress orchestrates feedback between AMPK and SQSTM1/p62 to confer synergistic antioxidant defense via dual activation of AMPK and NFE2L2.

Key Innovation from the Reference Study

The central innovation of this work is the discovery of a double-positive feedback loop between AMPK and SQSTM1/p62 that is initiated by metabolic stress. The authors demonstrate that this loop leads to simultaneous activation of AMPK—a master regulator of energy balance—and NFE2L2/NRF2, a pivotal transcription factor mediating antioxidant responses. This dual activation is achieved through SQSTM1-mediated autophagic degradation of KEAP1 (thus releasing NFE2L2) and by facilitating AXIN–STK11–AMPK complex formation on lysosomal membranes. Notably, the feedback is bidirectional: AMPK activity is also required for metabolic stress-induced expression and phosphorylation of SQSTM1, completing the loop. This mechanism provides a molecular explanation for the frequent co-occurrence of STK11 and KEAP1 mutations in NSCLC, as it reveals a compensatory system in metabolic adaptation and redox homeostasis (reference).

Methods and Experimental Design Insights

The research employs a suite of molecular, biochemical, and cell biology approaches across multiple cell types, including NSCLC models and mouse embryonic fibroblasts. Key methodological highlights include:

• Induction of metabolic stress via glucose deprivation and monitoring of cellular responses using immunoblotting for phosphorylation and expression of SQSTM1/p62, AMPK, and NFE2L2/NRF2.
• Assessment of lysosomal function, pH changes, and Ca²⁺ secretion using fluorescence-based probes and pharmacological agents (e.g., bafilomycin A1, concanamycin A).
• Use of genetic models and targeted knockdowns (siRNA/CRISPR) to dissect the roles of STK11, KEAP1, SQSTM1, and MAP3K7/TAK1.
• Phospho-mutant constructs to pinpoint critical phosphorylation sites on SQSTM1 (S24 and S226) required for AMPK and NFE2L2 activation.
• Co-immunoprecipitation and lysosomal fractionation to map protein complex formation and subcellular localization dynamics.

This comprehensive strategy allowed the researchers to delineate both causal and correlative relationships among the studied pathways.

Core Findings and Why They Matter

Several interconnected discoveries were reported:

• Metabolic stress increases both the expression and phosphorylation of SQSTM1/p62, which is essential for activating the antioxidant NFE2L2 and energy-sensing AMPK pathways.
• SQSTM1/p62 drives dual activation by two mechanisms: (1) facilitating KEAP1 degradation (activating NFE2L2) and (2) promoting the assembly of the AXIN–STK11–AMPK complex at lysosomes (activating AMPK).
• The feedback is double-positive because AMPK activity is also necessary for SQSTM1 expression and phosphorylation under stress, with phosphorylation of S24 and S226 on SQSTM1 being critical for this effect.
• SQSTM1 expression is regulated by PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, events triggered by lysosomal deacidification under low-glucose, AMPK-activated conditions.
• SQSTM1 phosphorylation is mediated by MAP3K7/TAK1, itself activated by ROS and lysosomal Ca²⁺ efflux, placing TAK1 as a key upstream regulator in this stress-adaptive network.
• Disruption of the feedback loop or its components blunts both AMPK and NFE2L2 responses, decreasing antioxidant defenses and metabolic flexibility.
• Interestingly, supplying protons (via lactic acid) reverses the metabolic stress effects, highlighting the importance of lysosomal pH regulation.

These results provide a mechanistic framework for understanding why co-mutations in STK11 and KEAP1 frequently occur in NSCLC: redundancy in stress adaptation is likely required for tumor survival under fluctuating metabolic and oxidative pressures. The identification of the double-positive feedback loop reveals potential intervention points for disrupting cancer adaptation mechanisms.

Comparison with Existing Internal Articles

This new research expands on prior insights into inflammatory and stress signaling regulation. For example, the article "(5Z)-7-Oxozeaenol: Applied Protocols and Workflow Enhancements for TAK1 Inhibition" discusses the utility of (5Z)-7-Oxozeaenol as a highly selective and irreversible TAK1 inhibitor, a property directly relevant to this new study as MAP3K7/TAK1 is shown to be a crucial activator of SQSTM1 phosphorylation under metabolic stress. Furthermore, "(5Z)-7-Oxozeaenol: TAK1 Inhibition and Metabolic Stress Insights" connects TAK1 inhibition to metabolic adaptation, aligning with present findings that TAK1 is a nexus for stress-induced signaling cascades. These internal resources offer practical protocols and troubleshooting strategies for implementing TAK1 inhibition in cellular and animal models, supporting translation of the mechanistic insights from the reference study to experimental workflows.

Limitations and Transferability

While the study employs robust models and a multi-pronged experimental approach, several limitations merit consideration:

• The bulk of mechanistic data is derived from in vitro and ex vivo systems; in vivo confirmation (especially in clinical samples) remains needed to validate the universality of the feedback loop.
• Cell-type specificity and potential off-target effects of genetic or pharmacological interventions were not exhaustively profiled, which may influence transferability to other cancer types or physiological contexts.
• The interplay between tumor microenvironmental factors—such as immune cell infiltration and systemic metabolic status—was not addressed, suggesting further research is required to map these dynamics in situ.

Despite these restrictions, the findings offer a compelling molecular rationale for targeting metabolic stress adaptation in NSCLC and potentially other cancers exhibiting similar metabolic-oxidative stress interplay.

Protocol Parameters

• TAK1 inhibition in metabolic stress models: For cell-based studies, (5Z)-7-Oxozeaenol can be used at 500 nM with an incubation period of 17.5 hours to optimally block TAK1-mediated phosphorylation events, as reported in product information and corroborated by workflow articles.
• Inflammation model readouts: In animal models, topical administration of TAK1 inhibitors such as (5Z)-7-Oxozeaenol has demonstrated up to 50% reduction in swelling in picryl chloride-induced inflammation, supporting its use as an inflammation model compound.
• Controls and validation: Always include vehicle and pathway-specific positive controls (e.g., bafilomycin A1 for lysosomal acidification) to validate stress and signaling pathway modulation.
• Phospho-mutant constructs: Use site-directed mutagenesis to probe the functional consequences of SQSTM1 phosphorylation at S24 and S226, as these residues are critical for dual pathway activation.

Research Support Resources

For researchers seeking to replicate or extend these findings, selective TAK1 inhibitors such as (5Z)-7-Oxozeaenol (SKU B7443) are invaluable tools for dissecting the MAP3K7/TAK1–SQSTM1 axis in metabolic and inflammatory stress models. The compound’s high selectivity and potency make it suited for precise inhibition of TAK1-dependent phosphorylation events, facilitating investigation of the feedback mechanisms highlighted in the reference study. Detailed protocols and troubleshooting advice can be found in the internal articles cited above and the APExBIO product documentation.